Investments and investor services
FTSE 100 closes firmly in red as traders fret about trade
Stock markets in Europe have suffered severe declines as US-China trade tensions have heightened
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 13 of 21
Archive
BT to take centre stage as it reports full year numbers with dividend in focus
The week ahead includes updates from BT Group, Superdry, Morrisons, ITV, IAG, Barratt Developments, Direct Line, RSA Insurance and Imperial Brands
Archive
Proactive news snapshot: Xpediator, Kibo Energy, Mirada …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Loungers sees good start to first day of trading on AIM
A look at some of the biggest risers and fallers in London on Monday
Faron Pharma: Japanese data bears out earlier study result
Chief executive Dr Markku Jalkanen pointed out: “It appears likely that corticosteroid use diminished the treatment benefit of Traumakine in ARDS patients in the Japanese Phase III study."
FTSE 100 closes higher after US inflation data
It comes after latest data showed that core inflation in the US was flat last month (March) while consumer spending rose
Archive
Proactive news snapshot: Mosman Oil & Gas, Rose Petroleum, Vast Resources, Faron Pharmaceuticals …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Dev Clever slides after receiving go-ahead to deploy its "first live interactive experience"
A look at the day's major movers, including Vast Resources, Cyanconnode, Trackwise, Mosman, UKOG, 7digital, Scapa and easyHotel
Faron to target colorectal cancer patients in ongoing Clevegen study after early promise
Faron has recruited four people to its trial, and although all of them have reacted well to the drug so far, the colorectal cancer patient has seen the most dramatic response
Investments and investor services
Carnival sinks as it lowers full-year guidance
A look at the day's major movers, including Quartix, LiDCO, Convatec, PPHE, Boku and Coral Products
Archive
Proactive news snapshot: ValiRx, Erris Resources, Personal Group, S&U …
A glance at some of the day's highlights from the Proactive Investors newswire
Faron Pharma up on cancer trial positive as it raises €3.12mln to advance development programmes
The AIM-listed clinical-stage biopharmaceutical company said 864,164 shares were placed at a price of 60.0p each with institutional investors after an accelerated bookbuild process
Archive
FTSE 100 closes higher as global growth fears ease, but Carnival shares sink
The UK's premier index closed up nearly 19 points at 7,169, while FTSE 250 added over 96 at 8,896
Faron Pharma chief executive says Clevegen results suggest it can be a new tool against cancer
The first two patients dosed showed marked increases in natural killer (NK) cells and T-Cells
Archive
Proactive news snapshot: Faron Pharmaceuticals, Sunrise Resources, Tertiary Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
PCI-PAL surrenders some recent gains as half-year losses widen
A look at the day's major movers, including Gulf Marine Services, Argos Resources, Premier Technical Services, Serco, Vitec, Purplebricks and Centrica
Faron Pharma makes encouraging start in Clevegen solid tumour trial
There were noticeable increases in the body’s natural killer cells in the first two patients treated
Study shows cancer-fighting potential of anti-Clever-1 antibodies such as Faron Pharma’s Clevegen
Faron is currently taking Clevegen through its first in-human clinical trial, and research from a university in Finland has shown that blocking a cell receptor called Clever-1 can suppress tumours
Archive
Proactive news snapshot: Anglo African Oil & Gas, Clinigen Group, Norman Broadbent …
A glance at some of the day's highlights from the Proactive Investors newswire